Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?

A

admin

Administrator
Jun 17, 2007
66,216
0
36
49
Canada
Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY) are both eyeing the same pie, and they're both serious about getting a big slice. It's the market for antibody-drug conjugates (ADCs), an emerging but proven therapeutic modality that should really take off through the rest of the decade after a successful first act. Per a report by DataM Intelligence, the market for ADCs will reach a size of $16.6 billion by 2030, more than tripling its value of around $5 billion today.
 
You must log in or register to reply here.
Back
Top